nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2B6—Thiotepa—urinary bladder cancer	0.227	0.329	CbGbCtD
Carbinoxamine—CYP3A4—Thiotepa—urinary bladder cancer	0.0696	0.101	CbGbCtD
Carbinoxamine—CYP2B6—Cisplatin—urinary bladder cancer	0.0626	0.0907	CbGbCtD
Carbinoxamine—CYP2E1—Etoposide—urinary bladder cancer	0.0623	0.0904	CbGbCtD
Carbinoxamine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0558	0.0809	CbGbCtD
Carbinoxamine—CYP2C8—Etoposide—urinary bladder cancer	0.0466	0.0675	CbGbCtD
Carbinoxamine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0419	0.0608	CbGbCtD
Carbinoxamine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0389	0.0564	CbGbCtD
Carbinoxamine—CYP2C9—Cisplatin—urinary bladder cancer	0.033	0.0479	CbGbCtD
Carbinoxamine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0203	0.0294	CbGbCtD
Carbinoxamine—CYP3A4—Etoposide—urinary bladder cancer	0.0189	0.0274	CbGbCtD
Carbinoxamine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0129	0.0187	CbGbCtD
Carbinoxamine—CYP2C19—urine—urinary bladder cancer	0.00641	0.129	CbGeAlD
Carbinoxamine—CYP2C9—urine—urinary bladder cancer	0.00497	0.0998	CbGeAlD
Carbinoxamine—CYP2E1—urine—urinary bladder cancer	0.00471	0.0946	CbGeAlD
Carbinoxamine—Irritability—Valrubicin—urinary bladder cancer	0.00393	0.0266	CcSEcCtD
Carbinoxamine—Urinary retention—Valrubicin—urinary bladder cancer	0.00392	0.0265	CcSEcCtD
Carbinoxamine—CYP3A4—urine—urinary bladder cancer	0.00379	0.0761	CbGeAlD
Carbinoxamine—CYP2D6—urine—urinary bladder cancer	0.00373	0.0749	CbGeAlD
Carbinoxamine—Pollakiuria—Valrubicin—urinary bladder cancer	0.00329	0.0223	CcSEcCtD
Carbinoxamine—Neuritis—Gemcitabine—urinary bladder cancer	0.00222	0.015	CcSEcCtD
Carbinoxamine—Drowsiness—Mitomycin—urinary bladder cancer	0.00219	0.0148	CcSEcCtD
Carbinoxamine—HRH1—prostate gland—urinary bladder cancer	0.00176	0.0353	CbGeAlD
Carbinoxamine—CYP2E1—prostate gland—urinary bladder cancer	0.00169	0.034	CbGeAlD
Carbinoxamine—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00167	0.0113	CcSEcCtD
Carbinoxamine—Vision blurred—Mitomycin—urinary bladder cancer	0.00161	0.0109	CcSEcCtD
Carbinoxamine—Chest discomfort—Etoposide—urinary bladder cancer	0.0016	0.0108	CcSEcCtD
Carbinoxamine—Wheezing—Cisplatin—urinary bladder cancer	0.0015	0.0101	CcSEcCtD
Carbinoxamine—Asthenia—Valrubicin—urinary bladder cancer	0.00145	0.00984	CcSEcCtD
Carbinoxamine—CYP2E1—seminal vesicle—urinary bladder cancer	0.00143	0.0287	CbGeAlD
Carbinoxamine—Confusional state—Mitomycin—urinary bladder cancer	0.00141	0.00953	CcSEcCtD
Carbinoxamine—Euphoric mood—Fluorouracil—urinary bladder cancer	0.0014	0.00947	CcSEcCtD
Carbinoxamine—Diarrhoea—Valrubicin—urinary bladder cancer	0.00139	0.00939	CcSEcCtD
Carbinoxamine—CYP2C8—renal system—urinary bladder cancer	0.00137	0.0275	CbGeAlD
Carbinoxamine—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00137	0.00925	CcSEcCtD
Carbinoxamine—Urinary retention—Thiotepa—urinary bladder cancer	0.00136	0.0092	CcSEcCtD
Carbinoxamine—Photosensitivity—Fluorouracil—urinary bladder cancer	0.00134	0.00911	CcSEcCtD
Carbinoxamine—Dizziness—Valrubicin—urinary bladder cancer	0.00134	0.00907	CcSEcCtD
Carbinoxamine—Anorexia—Mitomycin—urinary bladder cancer	0.00133	0.00901	CcSEcCtD
Carbinoxamine—HRH1—epithelium—urinary bladder cancer	0.00129	0.026	CbGeAlD
Carbinoxamine—Vomiting—Valrubicin—urinary bladder cancer	0.00129	0.00872	CcSEcCtD
Carbinoxamine—Headache—Valrubicin—urinary bladder cancer	0.00127	0.00859	CcSEcCtD
Carbinoxamine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00125	0.025	CbGeAlD
Carbinoxamine—Somnolence—Mitomycin—urinary bladder cancer	0.00124	0.0084	CcSEcCtD
Carbinoxamine—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.00124	0.0084	CcSEcCtD
Carbinoxamine—Nasal congestion—Cisplatin—urinary bladder cancer	0.00123	0.00832	CcSEcCtD
Carbinoxamine—CYP2B6—renal system—urinary bladder cancer	0.00123	0.0247	CbGeAlD
Carbinoxamine—Decreased appetite—Mitomycin—urinary bladder cancer	0.00121	0.00822	CcSEcCtD
Carbinoxamine—Nausea—Valrubicin—urinary bladder cancer	0.0012	0.00815	CcSEcCtD
Carbinoxamine—Fatigue—Mitomycin—urinary bladder cancer	0.0012	0.00815	CcSEcCtD
Carbinoxamine—HRH1—urethra—urinary bladder cancer	0.00118	0.0237	CbGeAlD
Carbinoxamine—CYP2E1—renal system—urinary bladder cancer	0.00115	0.0231	CbGeAlD
Carbinoxamine—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00115	0.00779	CcSEcCtD
Carbinoxamine—CYP2C19—vagina—urinary bladder cancer	0.00114	0.0228	CbGeAlD
Carbinoxamine—CYP2E1—urethra—urinary bladder cancer	0.00113	0.0227	CbGeAlD
Carbinoxamine—Irritability—Fluorouracil—urinary bladder cancer	0.00113	0.00763	CcSEcCtD
Carbinoxamine—CYP2C8—female reproductive system—urinary bladder cancer	0.0011	0.022	CbGeAlD
Carbinoxamine—Irritability—Cisplatin—urinary bladder cancer	0.00107	0.00724	CcSEcCtD
Carbinoxamine—Neuritis—Epirubicin—urinary bladder cancer	0.00106	0.00718	CcSEcCtD
Carbinoxamine—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00103	0.00695	CcSEcCtD
Carbinoxamine—Asthenia—Mitomycin—urinary bladder cancer	0.001	0.00678	CcSEcCtD
Carbinoxamine—CYP2C8—vagina—urinary bladder cancer	0.000991	0.0199	CbGeAlD
Carbinoxamine—CYP2B6—female reproductive system—urinary bladder cancer	0.000983	0.0198	CbGeAlD
Carbinoxamine—Neuritis—Doxorubicin—urinary bladder cancer	0.000981	0.00665	CcSEcCtD
Carbinoxamine—CYP2C9—female reproductive system—urinary bladder cancer	0.000973	0.0196	CbGeAlD
Carbinoxamine—HRH1—female reproductive system—urinary bladder cancer	0.00096	0.0193	CbGeAlD
Carbinoxamine—Diarrhoea—Mitomycin—urinary bladder cancer	0.000955	0.00647	CcSEcCtD
Carbinoxamine—Sweating increased—Cisplatin—urinary bladder cancer	0.000942	0.00638	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.000932	0.00631	CcSEcCtD
Carbinoxamine—CYP3A4—renal system—urinary bladder cancer	0.000927	0.0186	CbGeAlD
Carbinoxamine—Dizziness—Mitomycin—urinary bladder cancer	0.000923	0.00625	CcSEcCtD
Carbinoxamine—CYP2E1—female reproductive system—urinary bladder cancer	0.000922	0.0185	CbGeAlD
Carbinoxamine—Tinnitus—Thiotepa—urinary bladder cancer	0.000921	0.00624	CcSEcCtD
Carbinoxamine—CYP2D6—renal system—urinary bladder cancer	0.000912	0.0183	CbGeAlD
Carbinoxamine—Neuropathy peripheral—Gemcitabine—urinary bladder cancer	0.000907	0.00615	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Fluorouracil—urinary bladder cancer	0.000892	0.00604	CcSEcCtD
Carbinoxamine—CYP2B6—vagina—urinary bladder cancer	0.000889	0.0179	CbGeAlD
Carbinoxamine—Vomiting—Mitomycin—urinary bladder cancer	0.000887	0.00601	CcSEcCtD
Carbinoxamine—Chills—Thiotepa—urinary bladder cancer	0.000886	0.006	CcSEcCtD
Carbinoxamine—Headache—Mitomycin—urinary bladder cancer	0.000874	0.00592	CcSEcCtD
Carbinoxamine—HRH1—vagina—urinary bladder cancer	0.000868	0.0174	CbGeAlD
Carbinoxamine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.000864	0.00585	CcSEcCtD
Carbinoxamine—Sweating increased—Etoposide—urinary bladder cancer	0.000863	0.00585	CcSEcCtD
Carbinoxamine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.000849	0.00575	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Cisplatin—urinary bladder cancer	0.000846	0.00573	CcSEcCtD
Carbinoxamine—Tension—Thiotepa—urinary bladder cancer	0.000844	0.00571	CcSEcCtD
Carbinoxamine—Nervousness—Thiotepa—urinary bladder cancer	0.000835	0.00566	CcSEcCtD
Carbinoxamine—Nausea—Mitomycin—urinary bladder cancer	0.000829	0.00561	CcSEcCtD
Carbinoxamine—Vision blurred—Thiotepa—urinary bladder cancer	0.00081	0.00549	CcSEcCtD
Carbinoxamine—Agitation—Thiotepa—urinary bladder cancer	0.00079	0.00535	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000775	0.00525	CcSEcCtD
Carbinoxamine—Chills—Gemcitabine—urinary bladder cancer	0.000745	0.00505	CcSEcCtD
Carbinoxamine—Convulsion—Thiotepa—urinary bladder cancer	0.000745	0.00505	CcSEcCtD
Carbinoxamine—CYP3A4—female reproductive system—urinary bladder cancer	0.000742	0.0149	CbGeAlD
Carbinoxamine—Agranulocytosis—Etoposide—urinary bladder cancer	0.000737	0.005	CcSEcCtD
Carbinoxamine—CYP2D6—female reproductive system—urinary bladder cancer	0.00073	0.0147	CbGeAlD
Carbinoxamine—Tinnitus—Cisplatin—urinary bladder cancer	0.000722	0.00489	CcSEcCtD
Carbinoxamine—Confusional state—Thiotepa—urinary bladder cancer	0.000707	0.00479	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—urinary bladder cancer	0.0007	0.00474	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000687	0.00465	CcSEcCtD
Carbinoxamine—Tachycardia—Thiotepa—urinary bladder cancer	0.000685	0.00464	CcSEcCtD
Carbinoxamine—Vision blurred—Fluorouracil—urinary bladder cancer	0.00067	0.00454	CcSEcCtD
Carbinoxamine—Anorexia—Thiotepa—urinary bladder cancer	0.000669	0.00453	CcSEcCtD
Carbinoxamine—Photosensitivity—Epirubicin—urinary bladder cancer	0.000655	0.00443	CcSEcCtD
Carbinoxamine—Chills—Etoposide—urinary bladder cancer	0.000637	0.00431	CcSEcCtD
Carbinoxamine—Vision blurred—Cisplatin—urinary bladder cancer	0.000635	0.0043	CcSEcCtD
Carbinoxamine—Tremor—Cisplatin—urinary bladder cancer	0.000632	0.00428	CcSEcCtD
Carbinoxamine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00063	0.00427	CcSEcCtD
Carbinoxamine—Somnolence—Thiotepa—urinary bladder cancer	0.000624	0.00423	CcSEcCtD
Carbinoxamine—Dyspepsia—Thiotepa—urinary bladder cancer	0.000618	0.00418	CcSEcCtD
Carbinoxamine—Convulsion—Fluorouracil—urinary bladder cancer	0.000616	0.00417	CcSEcCtD
Carbinoxamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.00061	0.00413	CcSEcCtD
Carbinoxamine—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000606	0.0041	CcSEcCtD
Carbinoxamine—Fatigue—Thiotepa—urinary bladder cancer	0.000605	0.0041	CcSEcCtD
Carbinoxamine—Constipation—Thiotepa—urinary bladder cancer	0.0006	0.00406	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—urinary bladder cancer	0.000586	0.00397	CcSEcCtD
Carbinoxamine—Confusional state—Fluorouracil—urinary bladder cancer	0.000585	0.00396	CcSEcCtD
Carbinoxamine—Convulsion—Cisplatin—urinary bladder cancer	0.000584	0.00396	CcSEcCtD
Carbinoxamine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000578	0.00392	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000578	0.00391	CcSEcCtD
Carbinoxamine—Diplopia—Epirubicin—urinary bladder cancer	0.000575	0.00389	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000571	0.00387	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000568	0.00385	CcSEcCtD
Carbinoxamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000566	0.00384	CcSEcCtD
Carbinoxamine—Anorexia—Gemcitabine—urinary bladder cancer	0.000563	0.00381	CcSEcCtD
Carbinoxamine—HRH1—lymph node—urinary bladder cancer	0.000562	0.0113	CbGeAlD
Carbinoxamine—Urticaria—Thiotepa—urinary bladder cancer	0.000557	0.00378	CcSEcCtD
Carbinoxamine—Vertigo—Etoposide—urinary bladder cancer	0.000555	0.00376	CcSEcCtD
Carbinoxamine—Anorexia—Fluorouracil—urinary bladder cancer	0.000553	0.00375	CcSEcCtD
Carbinoxamine—Hypotension—Gemcitabine—urinary bladder cancer	0.000552	0.00374	CcSEcCtD
Carbinoxamine—Hypotension—Fluorouracil—urinary bladder cancer	0.000542	0.00367	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000539	0.00365	CcSEcCtD
Carbinoxamine—Tachycardia—Cisplatin—urinary bladder cancer	0.000537	0.00364	CcSEcCtD
Carbinoxamine—Convulsion—Etoposide—urinary bladder cancer	0.000535	0.00362	CcSEcCtD
Carbinoxamine—Insomnia—Gemcitabine—urinary bladder cancer	0.000534	0.00362	CcSEcCtD
Carbinoxamine—Diplopia—Doxorubicin—urinary bladder cancer	0.000532	0.0036	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000532	0.0036	CcSEcCtD
Carbinoxamine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00053	0.00359	CcSEcCtD
Carbinoxamine—Insomnia—Fluorouracil—urinary bladder cancer	0.000525	0.00356	CcSEcCtD
Carbinoxamine—Somnolence—Gemcitabine—urinary bladder cancer	0.000525	0.00355	CcSEcCtD
Carbinoxamine—Anorexia—Cisplatin—urinary bladder cancer	0.000524	0.00355	CcSEcCtD
Carbinoxamine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000521	0.00353	CcSEcCtD
Carbinoxamine—Somnolence—Fluorouracil—urinary bladder cancer	0.000516	0.00349	CcSEcCtD
Carbinoxamine—Hypotension—Cisplatin—urinary bladder cancer	0.000514	0.00348	CcSEcCtD
Carbinoxamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000513	0.00348	CcSEcCtD
Carbinoxamine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000511	0.00346	CcSEcCtD
Carbinoxamine—Fatigue—Gemcitabine—urinary bladder cancer	0.000509	0.00345	CcSEcCtD
Carbinoxamine—Confusional state—Etoposide—urinary bladder cancer	0.000508	0.00344	CcSEcCtD
Carbinoxamine—Constipation—Gemcitabine—urinary bladder cancer	0.000505	0.00342	CcSEcCtD
Carbinoxamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000504	0.00342	CcSEcCtD
Carbinoxamine—Asthenia—Thiotepa—urinary bladder cancer	0.000503	0.00341	CcSEcCtD
Carbinoxamine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000494	0.00335	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000493	0.00334	CcSEcCtD
Carbinoxamine—Tachycardia—Etoposide—urinary bladder cancer	0.000492	0.00333	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000487	0.0033	CcSEcCtD
Carbinoxamine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000486	0.00329	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000485	0.00328	CcSEcCtD
Carbinoxamine—Anorexia—Etoposide—urinary bladder cancer	0.00048	0.00325	CcSEcCtD
Carbinoxamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00048	0.00325	CcSEcCtD
Carbinoxamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000478	0.00324	CcSEcCtD
Carbinoxamine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000478	0.00324	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—urinary bladder cancer	0.000473	0.00321	CcSEcCtD
Carbinoxamine—Hypotension—Etoposide—urinary bladder cancer	0.000471	0.00319	CcSEcCtD
Carbinoxamine—Dizziness—Thiotepa—urinary bladder cancer	0.000464	0.00314	CcSEcCtD
Carbinoxamine—Urticaria—Fluorouracil—urinary bladder cancer	0.000461	0.00312	CcSEcCtD
Carbinoxamine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000459	0.00311	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000453	0.00307	CcSEcCtD
Carbinoxamine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000453	0.00307	CcSEcCtD
Carbinoxamine—Paraesthesia—Etoposide—urinary bladder cancer	0.000453	0.00307	CcSEcCtD
Carbinoxamine—Somnolence—Etoposide—urinary bladder cancer	0.000448	0.00304	CcSEcCtD
Carbinoxamine—Vomiting—Thiotepa—urinary bladder cancer	0.000446	0.00302	CcSEcCtD
Carbinoxamine—Drowsiness—Epirubicin—urinary bladder cancer	0.000443	0.003	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000442	0.00299	CcSEcCtD
Carbinoxamine—Headache—Thiotepa—urinary bladder cancer	0.00044	0.00298	CcSEcCtD
Carbinoxamine—Decreased appetite—Etoposide—urinary bladder cancer	0.000438	0.00297	CcSEcCtD
Carbinoxamine—Fatigue—Etoposide—urinary bladder cancer	0.000435	0.00294	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000434	0.00294	CcSEcCtD
Carbinoxamine—Constipation—Etoposide—urinary bladder cancer	0.000431	0.00292	CcSEcCtD
Carbinoxamine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000425	0.00288	CcSEcCtD
Carbinoxamine—Asthenia—Gemcitabine—urinary bladder cancer	0.000423	0.00287	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00042	0.00284	CcSEcCtD
Carbinoxamine—Nausea—Thiotepa—urinary bladder cancer	0.000417	0.00282	CcSEcCtD
Carbinoxamine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000415	0.00281	CcSEcCtD
Carbinoxamine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000413	0.0028	CcSEcCtD
Carbinoxamine—Drowsiness—Doxorubicin—urinary bladder cancer	0.00041	0.00278	CcSEcCtD
Carbinoxamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000404	0.00274	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000402	0.00272	CcSEcCtD
Carbinoxamine—Urticaria—Etoposide—urinary bladder cancer	0.0004	0.00271	CcSEcCtD
Carbinoxamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000397	0.00269	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—urinary bladder cancer	0.000396	0.00268	CcSEcCtD
Carbinoxamine—Asthenia—Cisplatin—urinary bladder cancer	0.000395	0.00267	CcSEcCtD
Carbinoxamine—Dizziness—Fluorouracil—urinary bladder cancer	0.000384	0.0026	CcSEcCtD
Carbinoxamine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000383	0.00259	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—urinary bladder cancer	0.000381	0.00258	CcSEcCtD
Carbinoxamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000376	0.00255	CcSEcCtD
Carbinoxamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000375	0.00254	CcSEcCtD
Carbinoxamine—Tinnitus—Epirubicin—urinary bladder cancer	0.000371	0.00251	CcSEcCtD
Carbinoxamine—Headache—Gemcitabine—urinary bladder cancer	0.00037	0.0025	CcSEcCtD
Carbinoxamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000369	0.0025	CcSEcCtD
Carbinoxamine—Headache—Fluorouracil—urinary bladder cancer	0.000364	0.00246	CcSEcCtD
Carbinoxamine—Asthenia—Etoposide—urinary bladder cancer	0.000362	0.00245	CcSEcCtD
Carbinoxamine—Chills—Epirubicin—urinary bladder cancer	0.000357	0.00242	CcSEcCtD
Carbinoxamine—Nausea—Gemcitabine—urinary bladder cancer	0.000351	0.00237	CcSEcCtD
Carbinoxamine—Vomiting—Cisplatin—urinary bladder cancer	0.00035	0.00237	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—urinary bladder cancer	0.000349	0.00236	CcSEcCtD
Carbinoxamine—Diarrhoea—Etoposide—urinary bladder cancer	0.000345	0.00234	CcSEcCtD
Carbinoxamine—Nausea—Fluorouracil—urinary bladder cancer	0.000345	0.00234	CcSEcCtD
Carbinoxamine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000343	0.00232	CcSEcCtD
Carbinoxamine—Tension—Epirubicin—urinary bladder cancer	0.00034	0.0023	CcSEcCtD
Carbinoxamine—Nervousness—Epirubicin—urinary bladder cancer	0.000336	0.00228	CcSEcCtD
Carbinoxamine—Dizziness—Etoposide—urinary bladder cancer	0.000333	0.00226	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—urinary bladder cancer	0.000332	0.00225	CcSEcCtD
Carbinoxamine—Chills—Doxorubicin—urinary bladder cancer	0.00033	0.00224	CcSEcCtD
Carbinoxamine—Nausea—Cisplatin—urinary bladder cancer	0.000327	0.00221	CcSEcCtD
Carbinoxamine—Vision blurred—Epirubicin—urinary bladder cancer	0.000326	0.00221	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—urinary bladder cancer	0.00032	0.00217	CcSEcCtD
Carbinoxamine—Vomiting—Etoposide—urinary bladder cancer	0.00032	0.00217	CcSEcCtD
Carbinoxamine—Agitation—Epirubicin—urinary bladder cancer	0.000318	0.00215	CcSEcCtD
Carbinoxamine—Headache—Etoposide—urinary bladder cancer	0.000316	0.00214	CcSEcCtD
Carbinoxamine—Tension—Doxorubicin—urinary bladder cancer	0.000314	0.00213	CcSEcCtD
Carbinoxamine—Nervousness—Doxorubicin—urinary bladder cancer	0.000311	0.00211	CcSEcCtD
Carbinoxamine—Vertigo—Epirubicin—urinary bladder cancer	0.000311	0.00211	CcSEcCtD
Carbinoxamine—Palpitations—Epirubicin—urinary bladder cancer	0.000306	0.00207	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—urinary bladder cancer	0.000304	0.00206	CcSEcCtD
Carbinoxamine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000302	0.00204	CcSEcCtD
Carbinoxamine—Convulsion—Epirubicin—urinary bladder cancer	0.0003	0.00203	CcSEcCtD
Carbinoxamine—Nausea—Etoposide—urinary bladder cancer	0.000299	0.00203	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000296	0.002	CcSEcCtD
Carbinoxamine—Agitation—Doxorubicin—urinary bladder cancer	0.000294	0.00199	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000292	0.00198	CcSEcCtD
Carbinoxamine—Vertigo—Doxorubicin—urinary bladder cancer	0.000288	0.00195	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—urinary bladder cancer	0.000288	0.00195	CcSEcCtD
Carbinoxamine—Confusional state—Epirubicin—urinary bladder cancer	0.000285	0.00193	CcSEcCtD
Carbinoxamine—Palpitations—Doxorubicin—urinary bladder cancer	0.000283	0.00192	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—urinary bladder cancer	0.000282	0.00191	CcSEcCtD
Carbinoxamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000278	0.00188	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000277	0.00187	CcSEcCtD
Carbinoxamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000276	0.00187	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000273	0.00185	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—urinary bladder cancer	0.000273	0.00185	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000271	0.00184	CcSEcCtD
Carbinoxamine—Anorexia—Epirubicin—urinary bladder cancer	0.000269	0.00182	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—urinary bladder cancer	0.000268	0.00182	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000266	0.0018	CcSEcCtD
Carbinoxamine—Hypotension—Epirubicin—urinary bladder cancer	0.000264	0.00179	CcSEcCtD
Carbinoxamine—Confusional state—Doxorubicin—urinary bladder cancer	0.000264	0.00179	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000262	0.00178	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—urinary bladder cancer	0.00026	0.00176	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000256	0.00173	CcSEcCtD
Carbinoxamine—Insomnia—Epirubicin—urinary bladder cancer	0.000256	0.00173	CcSEcCtD
Carbinoxamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000255	0.00173	CcSEcCtD
Carbinoxamine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000254	0.00172	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000253	0.00171	CcSEcCtD
Carbinoxamine—Somnolence—Epirubicin—urinary bladder cancer	0.000251	0.0017	CcSEcCtD
Carbinoxamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000249	0.00169	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000249	0.00169	CcSEcCtD
Carbinoxamine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000249	0.00168	CcSEcCtD
Carbinoxamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000246	0.00166	CcSEcCtD
Carbinoxamine—Hypotension—Doxorubicin—urinary bladder cancer	0.000244	0.00165	CcSEcCtD
Carbinoxamine—Fatigue—Epirubicin—urinary bladder cancer	0.000244	0.00165	CcSEcCtD
Carbinoxamine—Constipation—Epirubicin—urinary bladder cancer	0.000242	0.00164	CcSEcCtD
Carbinoxamine—Urticaria—Methotrexate—urinary bladder cancer	0.00024	0.00162	CcSEcCtD
Carbinoxamine—Insomnia—Doxorubicin—urinary bladder cancer	0.000236	0.0016	CcSEcCtD
Carbinoxamine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000235	0.00159	CcSEcCtD
Carbinoxamine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000233	0.00158	CcSEcCtD
Carbinoxamine—Somnolence—Doxorubicin—urinary bladder cancer	0.000232	0.00157	CcSEcCtD
Carbinoxamine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00023	0.00156	CcSEcCtD
Carbinoxamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000227	0.00154	CcSEcCtD
Carbinoxamine—Fatigue—Doxorubicin—urinary bladder cancer	0.000225	0.00153	CcSEcCtD
Carbinoxamine—Urticaria—Epirubicin—urinary bladder cancer	0.000224	0.00152	CcSEcCtD
Carbinoxamine—Constipation—Doxorubicin—urinary bladder cancer	0.000224	0.00151	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—urinary bladder cancer	0.000217	0.00147	CcSEcCtD
Carbinoxamine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000215	0.00146	CcSEcCtD
Carbinoxamine—Urticaria—Doxorubicin—urinary bladder cancer	0.000208	0.00141	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000207	0.0014	CcSEcCtD
Carbinoxamine—Asthenia—Epirubicin—urinary bladder cancer	0.000203	0.00137	CcSEcCtD
Carbinoxamine—Dizziness—Methotrexate—urinary bladder cancer	0.0002	0.00135	CcSEcCtD
Carbinoxamine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000193	0.00131	CcSEcCtD
Carbinoxamine—Vomiting—Methotrexate—urinary bladder cancer	0.000192	0.0013	CcSEcCtD
Carbinoxamine—Headache—Methotrexate—urinary bladder cancer	0.000189	0.00128	CcSEcCtD
Carbinoxamine—Asthenia—Doxorubicin—urinary bladder cancer	0.000188	0.00127	CcSEcCtD
Carbinoxamine—Dizziness—Epirubicin—urinary bladder cancer	0.000187	0.00127	CcSEcCtD
Carbinoxamine—Vomiting—Epirubicin—urinary bladder cancer	0.00018	0.00122	CcSEcCtD
Carbinoxamine—Nausea—Methotrexate—urinary bladder cancer	0.000179	0.00121	CcSEcCtD
Carbinoxamine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000179	0.00121	CcSEcCtD
Carbinoxamine—Headache—Epirubicin—urinary bladder cancer	0.000177	0.0012	CcSEcCtD
Carbinoxamine—Dizziness—Doxorubicin—urinary bladder cancer	0.000173	0.00117	CcSEcCtD
Carbinoxamine—Nausea—Epirubicin—urinary bladder cancer	0.000168	0.00114	CcSEcCtD
Carbinoxamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000166	0.00113	CcSEcCtD
Carbinoxamine—Headache—Doxorubicin—urinary bladder cancer	0.000164	0.00111	CcSEcCtD
Carbinoxamine—Nausea—Doxorubicin—urinary bladder cancer	0.000155	0.00105	CcSEcCtD
Carbinoxamine—CYP2E1—Metabolism—GSTZ1—urinary bladder cancer	9.16e-05	0.000808	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GSTO2—urinary bladder cancer	8.86e-05	0.000782	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—NAT1—urinary bladder cancer	8.86e-05	0.000782	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GSTO2—urinary bladder cancer	8.68e-05	0.000766	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—NAT1—urinary bladder cancer	8.68e-05	0.000766	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	8.11e-05	0.000716	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—UGT2B7—urinary bladder cancer	7.94e-05	0.000701	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	7.92e-05	0.000699	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	7.5e-05	0.000662	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—NAT1—urinary bladder cancer	7.5e-05	0.000662	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.38e-05	0.000651	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	7.3e-05	0.000644	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CYP4B1—urinary bladder cancer	7.15e-05	0.000631	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	7.07e-05	0.000624	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.94e-05	0.000612	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	6.89e-05	0.000608	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	6.86e-05	0.000606	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.84e-05	0.000604	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—SLC19A1—urinary bladder cancer	6.75e-05	0.000596	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	6.72e-05	0.000593	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NAT1—urinary bladder cancer	6.7e-05	0.000591	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	6.7e-05	0.000591	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.59e-05	0.000581	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PRSS3—urinary bladder cancer	6.58e-05	0.000581	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	6.5e-05	0.000574	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	6.44e-05	0.000569	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.37e-05	0.000563	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.29e-05	0.000555	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HDAC4—urinary bladder cancer	6.27e-05	0.000553	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	6.18e-05	0.000545	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	6.16e-05	0.000544	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	6.16e-05	0.000544	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	6.13e-05	0.000541	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	6.11e-05	0.000539	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	6.11e-05	0.000539	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.01e-05	0.00053	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	5.84e-05	0.000515	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	5.69e-05	0.000502	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	5.63e-05	0.000497	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.59e-05	0.000493	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	5.56e-05	0.00049	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	5.52e-05	0.000487	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	5.49e-05	0.000484	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—TYMP—urinary bladder cancer	5.37e-05	0.000474	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—TYMP—urinary bladder cancer	5.26e-05	0.000464	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—GLI1—urinary bladder cancer	5.25e-05	0.000464	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	5.21e-05	0.00046	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	5.18e-05	0.000457	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.08e-05	0.000448	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	5.07e-05	0.000448	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	5.03e-05	0.000444	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—NAT2—urinary bladder cancer	4.86e-05	0.000429	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.79e-05	0.000423	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—NAT2—urinary bladder cancer	4.76e-05	0.00042	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.75e-05	0.000419	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	4.67e-05	0.000412	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.63e-05	0.000409	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.56e-05	0.000402	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—TYMP—urinary bladder cancer	4.55e-05	0.000401	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.4e-05	0.000389	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.37e-05	0.000385	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.25e-05	0.000375	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	4.23e-05	0.000374	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—RRM2—urinary bladder cancer	4.19e-05	0.00037	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—NAT2—urinary bladder cancer	4.11e-05	0.000363	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—RRM2—urinary bladder cancer	4.11e-05	0.000362	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.07e-05	0.000359	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.06e-05	0.000358	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.03e-05	0.000356	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.03e-05	0.000356	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.9e-05	0.000344	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ENO2—urinary bladder cancer	3.88e-05	0.000343	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	3.88e-05	0.000343	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ENO2—urinary bladder cancer	3.8e-05	0.000336	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	3.8e-05	0.000336	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	3.77e-05	0.000332	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.73e-05	0.000329	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.71e-05	0.000328	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.7e-05	0.000327	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	3.69e-05	0.000326	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.68e-05	0.000325	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.67e-05	0.000324	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	3.6e-05	0.000318	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.55e-05	0.000314	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	3.55e-05	0.000313	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	3.39e-05	0.000299	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.38e-05	0.000298	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.35e-05	0.000295	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.32e-05	0.000293	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	3.29e-05	0.00029	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	3.29e-05	0.00029	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.27e-05	0.000288	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	3.22e-05	0.000284	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	3.19e-05	0.000281	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.17e-05	0.00028	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.14e-05	0.000277	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.13e-05	0.000276	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—NQO1—urinary bladder cancer	3.13e-05	0.000276	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—NQO1—urinary bladder cancer	3.07e-05	0.000271	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.05e-05	0.000269	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.93e-05	0.000259	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.93e-05	0.000259	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.92e-05	0.000257	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.91e-05	0.000257	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.89e-05	0.000255	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.85e-05	0.000251	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.8e-05	0.000247	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	2.72e-05	0.00024	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.7e-05	0.000238	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.7e-05	0.000238	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.68e-05	0.000236	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.68e-05	0.000236	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.66e-05	0.000235	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.65e-05	0.000234	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.62e-05	0.000231	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	2.61e-05	0.00023	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	2.61e-05	0.00023	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.59e-05	0.000229	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.57e-05	0.000227	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	2.56e-05	0.000226	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.56e-05	0.000226	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	2.47e-05	0.000218	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.44e-05	0.000215	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	2.43e-05	0.000214	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	2.4e-05	0.000212	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	2.4e-05	0.000212	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.39e-05	0.000211	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—TYMS—urinary bladder cancer	2.38e-05	0.00021	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.37e-05	0.000209	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	2.35e-05	0.000207	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	2.35e-05	0.000207	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	2.35e-05	0.000207	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	2.3e-05	0.000203	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.29e-05	0.000203	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	2.29e-05	0.000202	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	2.26e-05	0.000199	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GPX1—urinary bladder cancer	2.25e-05	0.000199	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.24e-05	0.000198	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.21e-05	0.000195	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	2.21e-05	0.000195	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.21e-05	0.000195	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.18e-05	0.000192	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.17e-05	0.000192	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.16e-05	0.00019	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.14e-05	0.000189	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	2.12e-05	0.000187	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.09e-05	0.000185	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	2.08e-05	0.000183	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	2.08e-05	0.000183	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	2.07e-05	0.000183	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.05e-05	0.000181	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.03e-05	0.000179	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.03e-05	0.000179	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2e-05	0.000177	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.97e-05	0.000174	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.94e-05	0.000172	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.91e-05	0.000169	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.91e-05	0.000168	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.91e-05	0.000168	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.9e-05	0.000167	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.84e-05	0.000163	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.83e-05	0.000162	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.82e-05	0.000161	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.81e-05	0.00016	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.81e-05	0.00016	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.81e-05	0.00016	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.8e-05	0.000159	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.79e-05	0.000158	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.76e-05	0.000156	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.76e-05	0.000156	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.74e-05	0.000154	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.74e-05	0.000153	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.72e-05	0.000152	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.71e-05	0.000151	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.7e-05	0.00015	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.000149	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.68e-05	0.000149	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.67e-05	0.000148	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000147	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000147	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.65e-05	0.000146	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.65e-05	0.000146	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.65e-05	0.000146	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.62e-05	0.000143	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.62e-05	0.000143	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.6e-05	0.000141	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.6e-05	0.000141	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.6e-05	0.000141	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.59e-05	0.00014	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.58e-05	0.00014	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	0.000138	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.55e-05	0.000137	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.5e-05	0.000132	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.47e-05	0.00013	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.46e-05	0.000129	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.46e-05	0.000129	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.46e-05	0.000128	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.42e-05	0.000126	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.4e-05	0.000123	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.35e-05	0.000119	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.35e-05	0.000119	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.32e-05	0.000117	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.3e-05	0.000115	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.28e-05	0.000113	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.27e-05	0.000113	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.25e-05	0.00011	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.23e-05	0.000108	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.2e-05	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.19e-05	0.000105	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.19e-05	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.18e-05	0.000105	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.18e-05	0.000104	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.16e-05	0.000102	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.16e-05	0.000102	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.16e-05	0.000102	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.15e-05	0.000102	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	0.000101	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.14e-05	0.000101	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.14e-05	0.0001	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.12e-05	9.93e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.1e-05	9.73e-05	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.1e-05	9.72e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.1e-05	9.71e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.09e-05	9.62e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.09e-05	9.62e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.07e-05	9.44e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.04e-05	9.21e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	9.05e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.02e-05	9.02e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	9.98e-06	8.81e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.63e-06	8.5e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	9.59e-06	8.46e-05	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—EP300—urinary bladder cancer	9.52e-06	8.4e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	9.4e-06	8.3e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	9.38e-06	8.28e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	9.32e-06	8.22e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	8.91e-06	7.87e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	8.86e-06	7.82e-05	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—EP300—urinary bladder cancer	8.5e-06	7.5e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	8.2e-06	7.23e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	8.13e-06	7.17e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	7.87e-06	6.95e-05	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	7.82e-06	6.9e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.81e-06	6.89e-05	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.75e-06	6.84e-05	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	7.53e-06	6.65e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.5e-06	6.62e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.15e-06	5.42e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.36e-06	4.73e-05	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.11e-06	4.51e-05	CbGpPWpGaD
